ReNeuron Group Long Term Debt 2017-2023 | RNUGF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ReNeuron Group long term debt from 2017 to 2023. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ReNeuron Group long term debt from 2017 to 2023. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.3B
Zoetis (ZTS)	$67.7B
Daiichi Sankyo, - (DSNKY)	$46.4B
Takeda Pharmaceutical (TAK)	$46.1B
BeOne Medicines - (ONC)	$31.9B
Sandoz Group AG (SDZNY)	$26.1B
Summit Therapeutics (SMMT)	$21.3B
Merck (MKKGY)	$17.2B
Shionogi (SGIOY)	$14.6B
United Therapeutics (UTHR)	$13.7B
Neurocrine Biosciences (NBIX)	$13.1B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$10.9B
Stevanato Group S.p.A (STVN)	$8B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.7B
Madrigal Pharmaceuticals (MDGL)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$2.9B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.8B